Health Condition 1: E669- Obesity, unspecified Health Condition 2: E663- Overweight
Conditions
Interventions
Intervention1: ACV Moringa Effervescent Tablet 4.3 g: Mode of Administration: Dissolve one effervescent tablet in a full glass of water in 200 mL. Allow it to fully dissolve before consuming. For bes
Sponsors
Zywie Ventures Private Ltd
Eligibility
Inclusion criteria
Inclusion criteria: 1) Age: 18- 65 years (both inclusive) at the time of consent. 2) Sex: Males and non-pregnant/non-lactating females (preferably equal number of males and females). 3) Females of childbearing potential must have a self-reported negative urine pregnancy. 4) Female of childbearing potential must have a reported negative pregnancy during screening and the end of the study 5) Subject is in good general health as determined by the Investigator on the basis of medical history. 6) Subjects who are classified as overweight (BMI 25.0 29.9 kg/m ) or as having Class I obesity (BMI 30.0 34.9 kg/m ). 7) Subjects with a total body fat percentage exceeding 25% for men and 30% for women using Bioimpedance test. 8) Subject is willing to forgo liposuction procedures or any weight loss therapy 3 months prior to and for the duration of the study. 9) Subject is able to remain on stable doses of contraceptive or replacement hormonal therapy, including no therapy, 6 weeks prior to and for the duration of the study. 10) If the female subject is of childbearing potential, is practicing and agrees to maintain an established method of birth control (IUD, hormonal implant device/injection, regular use of birth control pills or patch, diaphragm, condoms with spermicide or sponge with spermicidal jelly, cream or foam, partner vasectomy or abstinence). Females will be considered as non-childbearing potential if they are surgically sterile, have been post-menopausal for at least 1 year or have had a tubal ligation. 11) If currently using hormonal contraception, has been using this form of contraception for at least 6 months and agrees to continue using the same contraception for the duration of the study. 12) Subject who agree to consume a vegetarian/non-vegetarian diet of approximately 2000 kcal/day (14% protein, 25%Fat and 61% carbohydrate). 13) Subjects willing to follow the given diet and maintain their physical activity by a Diet and physical activity diary. 14) Subjects must possess an Android smartphone to facilitate daily app login and study-related activities. 15) Subjects are willing to give written informed consent and are willing to follow the study procedure. 16) Subjects who commit not to use any other medication for weight management other than the test treatment for the entire duration of the study. 17) Willing to use test treatment throughout the study period. 18) Subject is willing and able to follow the study directions, to participate in the study, returning for all specified visits.
Exclusion criteria
Exclusion criteria: 1) Subjects BMI is between less than 25 and greater than 35 kg/m2. 2) Subjects having past or present history or clinically significant findings indicating cardiovascular disease, type 2 diabetes mellitus, hypertension, endocrine, pulmonary, neurological or psychological disorders, hypo or hyperthyroidism and renal disorders. 3) Subjects with a history of gastrointestinal disorders, including chronic gastritis, gastric discomfort, or any diagnosed gastrointestinal conditions. 4) Subjects having drug and alcohol abuse. 5) Smokers and tobacco users. 6) Subjects having more than 5 kg variation in body weight within 3 months before study entry. 7) Subjects using other weight loss medications, as well as stimulants, laxatives or diuretics taken solely for the purpose of weight loss. 8) Undergone surgery before 30 days of screening or planning to undergo surgery within the study period. 9) Subjects having chronic diarrhoeal disorders, cancer, hepatic dysfunction, and human immunodeficiency virus (HIV) infection. 10) Participation in other drugs, investigational medicinal product, any herbal products and/or cosmetics intended to weight loss clinical trials within 3 months before enrolment in this trial. 11) Any other diseases/co-morbidity that is considered by the Investigator as an exclusion. 12) With severe hepatic and/or renal impairment, liver enzyme level (ALT and/or AST) is greater than 2.5 times the upper normal limit. 13) Taking antibiotic therapy, anti-depressant treatment or treatment related to anxiety in the month preceding the study, 14) Taking anti-depressant treatment or treatment related to anxiety Subject in a state of depression. 15) Non-stable weight during the last 6 months (more than 5% change in total weight) 16) Consuming food supplements or functional foods known to have an influence on weight management in the month preceding the inclusion and/or likely to take during the test 17) Following or having followed a hypocaloric diet (energy intake less than 1,500 kCal/day) in the month preceding inclusion and/or likely to undertake this diet during the test. 18) Diagnosed eating disorders (bulimia, anorexia nervosa, vomiting), 19) Using topical anti-cellulite treatments. 20) Pregnant or breastfeeding or planning to become pregnant during the study period. 21) Subject has a history of chronic illness which may influence the cutaneous state. 22) Subjects participating in other similar nutraceuticals, food, supplemental or therapeutic trials within the last four weeks. 23) Any other condition which could warrant exclusion from the study, as per the Investigator s discretion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1.To assess the efficacy of test treatment by evaluating change in Body Weight using calibrated weighing machine at three predefined time points- Day 01 (pre-treatment), Day 45 (+2 days), and Day 90 (+2 days), assessed within each treatment group and across treatment groups.Timepoint: Day 01 (pre-treatment), Day 45 (+2 days), and Day 90 (+2 days) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.To assess the efficacy of test treatment by evaluating change in Anthropometric Parameters using calibrated measuring tape assessed within each treatment group and across treatment groupsTimepoint: Day 01 , Day 45 , and Day 90;2.To assess the efficacy of test treatment by evaluating change in Total Fat Percentage using Bioimpedance Test assessed within each treatment group and across treatment groups.Timepoint: Day 01 , Day 45 , and Day 90;3. To assess the efficacy of test treatment by evaluating change in VO2 Max using Treadmill Walking Test assessed within each treatment group and across treatment groupsTimepoint: Day 01 , Day 45 , and Day 90;4. To assess the efficacy of test treatment by evaluating change in Apolipoprotein- ApoA, ApoB, assessed within each treatment group and across treatment groups.Timepoint: Day 01 , Day 45 , and Day 90;5.To assess the efficacy of test treatment by evaluating change in carbohydrate metabolism through Serum Blood Glucose and PPBG assessed within each treatment group and across treatment groups.Timepoint: Day 01 , Day 45 and Day 90;6. To assess the efficacy of test treatment by evaluating change in Lipid metabolism through Total Cholesterol, HDL, LDL, Triglycerides assessed within each treatment group and across treatment groups.Timepoint: 30 Days from Day 01, Day 01 , Day 45 , and Day 90;7. To assess the efficacy of test treatment by evaluating change in Fatty Acid Oxidation Rate through Beta-hydroxybutyrate, assessed within each treatment group and across treatment groupsTimepoint: Day 01 , Day 45 , and Day 90;8. To assess the efficacy of test treatment by evaluating change in Metabolic Biomarkers through HOMA-IR , assessed within each treatment group and across treatment groupsTimepoint: Day 01 and Day 90;9. To assess the efficacy of test treatment by evaluating change in Inflammatory Biomarkers through IL-6, CRP, assessed within each treatment group and across treatment groupsTimepoint: Day 01 , Day 45 , and Day 90 | — |
Countries
India
Contacts
Public ContactMaheshvari Patel
NovoBliss Research Pvt. Ltd.
Outcome results
None listed